Document is current
Any future updates will be listed below
-
Authors
Gefard-Gontier, E.
Markich, R.
Zysman, M.
Veillon, R.
Daste, A.
Domblides, C.
Sionneau, B.
Gross-Goupil, M.
Lefort, F.
Prey, S.
Dutriaux, C.
Gerard, E.
Dousset, L.
Pham-Ledard, A.
Beylot-Barry, M.
Schaeverbeke, T.
Kostine, M. https://orcid.org/0000-0002-6729-6200
- License Information
-
More Information
Article History
Received: 8 November 2021
Accepted: 16 February 2022
First Online: 19 March 2022
Declarations
:
: APL reports travel and accommodation support from BMS. CD reports travel and accommodation support from AstraZeneca, BMS, MSD and Roche and advisory board for AstraZeneca. MK reports speaker fees for BMS. All the others authors declared no conflict of interest for this work.
: The study was approved by local institutional review board (CERBDX 2021-44).
